On June 27, 2025, Ascendis Pharma A/S closed an exercise window for outstanding warrants, resulting in an increase in share capital by DKK 180,898, totaling a new share capital of DKK 61,151,463 through the issuance of 180,898 shares at approximately USD $80.61 each.